Adrian G. Rawcliffe
Net Worth
Last updated:
What is Adrian G. Rawcliffe net worth?
The estimated net worth of Mr. Adrian G. Rawcliffe is at least $8,415,410 as of 17 Jan 2024. He owns shares worth $2,740 as insider, has earned $1,508,850 from insider trading and has received compensation worth at least $6,903,820 in Adaptimmune Therapeutics plc.
What is the salary of Adrian G. Rawcliffe?
Mr. Adrian G. Rawcliffe salary is $986,260 per year as Chief Executive Officer, Principal Accounting Officer & Director in Adaptimmune Therapeutics plc.
How old is Adrian G. Rawcliffe?
Mr. Adrian G. Rawcliffe is 53 years old, born in 1972.
What stocks does Adrian G. Rawcliffe currently own?
As insider, Mr. Adrian G. Rawcliffe owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Adaptimmune Therapeutics plc (ADAP) | Chief Executive Officer, Principal Accounting Officer & Director | 44,848 | $0.06 | $2,740 |
What does Adaptimmune Therapeutics plc do?
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Adrian G. Rawcliffe insider trading
Adaptimmune Therapeutics plc
Mr. Adrian G. Rawcliffe has made 27 insider trades between 2018-2024, according to the Form 4 filled with the SEC. Most recently he sold 30,080 units of ADAP stock worth $20,244 on 17 Jan 2024.
The largest trade he's ever made was exercising 600,000 units of ADAP stock on 20 Mar 2018. As of 17 Jan 2024 he still owns at least 44,848 units of ADAP stock.
Adaptimmune Therapeutics key executives
Adaptimmune Therapeutics plc executives and other stock owners filed with the SEC:
- Dr. Helen Katrina Tayton-Martin MBA, Ph.D. (58) Co-Founder & Chief Bus. Officer
- Mr. Adrian G. Rawcliffe (53) Chief Executive Officer, Principal Accounting Officer & Director
- Mr. Gavin Hilary James Wood BA (Hons), ACA (55) Chief Financial Officer
- Mr. John Lunger (55) Chief Patient Supply Officer
- Mr. William C. Bertrand Jr. (60) Chief Operating Officer